Best Adipotide (FTPP) 5mg and 10mg Peptides GMP Factory

Adipotide (FTPP)

Adipotide (FTPP)

Other names:Fat Targeted Proapoptotic Peptide, FTPP

Adipotide or FTPP (Fat Targeted Proapoptotic Peptide), is a synthetic peptide that has been studied for its possible application in the treatment of obesity and weight loss. The peptide is particularly engineered to target and cause apoptosis (programmed cell death) in blood arteries that supply white adipose tissue (fat cells).Adipotide’s primary mode of action involves targeting two domains in the body: the homing domain, which allows the peptide to target a protein called Prohibitin on the surface of blood vessel cells supplying adipose tissue, and the membrane-disrupting domain, which disrupts mitochondrial membranes in the targeted cells, resulting in apoptosis.

Production capacity: Provide customization

Large Factory Professional Manufacturers & Factory

Production Carried OUT Under CGMP Regulation and Trackable

ISO9001 & ISO14000

Get a Bulk quotation

If you need a larger quantity. Please fill in the form, our BD (Business Development) will provide you with a competitive quotation.

Adipotide (FTPP) Peptide dosage calculator

Referenced Citations

[1]Barnhart, K. F., Christianson, D. R., Hanley, P. W., … & Pasqualini, R. A peptidomimetic targeting white fat causes weight loss and improved insulin   resistance in obese monkeys. Science translational medicine, 2011. 

[2]Thuaud F, Ribeiro N, Nebigil CG, Désaubry L. Prohibitin ligands in cell death and survival: mode of action and therapeutic potential. Chem Biol. 2013;20(3):316-331.

[3] Daquinag AC, Tseng C, Salameh A, et al. Depletion of white adipocyte progenitors induces beige adipocyte differentiation and suppresses obesity development. Cell Death Differ. 2015;22(2):351-363.

[4]Kim DH, Sartor MA, Bain JR, Sandoval D, Stevens RD, Medvedovic M, Newgard CB, Woods SC, Seeley RJ. Rapid and weight-independent improvement of glucose tolerance induced by a peptide designed to elicit apoptosis in adipose tissue endothelium. Diabetes. 2012 Sep;61(9):2299-310.

[5]Smith, T. L., Sidman, R. L., Arap, W., & Pasqualini, R. (2022). Targeting vascular zip codes: from combinatorial selection to drug prototypes. In The Vasculome (pp. 393-401). Academic Press.

[6]Blaszczak AM, Jalilvand A, Hsueh WA. Adipocytes, Innate Immunity and Obesity: A Mini-Review. Front Immunol. 2021;12:650768. Published 2021 Jun 24.

[7]Staquicini FI, Cardó-Vila M, Kolonin MG, Trepel M, Edwards JK, Nunes DN, Sergeeva A, Efstathiou E, Sun J, Almeida NF, Tu SM, Botz GH, Wallace MJ, O’Connell DJ, Krajewski S, Gershenwald JE, Molldrem JJ, Flamm AL, Koivunen E, Pentz RD, Dias-Neto E, Setubal JC, Cahill DJ, Troncoso P, Do KA, Logothetis CJ, Sidman RL, Pasqualini R, Arap W. Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18637-42.

[8]Hossen N, Kajimoto K, Akita H, Hyodo M, Harashima H. A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication. J Control Release. 2013;171(2):104-112.

[9]Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W. Reversal of obesity by targeted ablation of adipose tissue. Nat Med. 2004 Jun;10(6):625-32.

[10]Salameh A, Daquinag AC, Staquicini DI, An Z, Hajjar KA, Pasqualini R, Arap W, Kolonin MG. Prohibitin/annexin 2 interaction regulates fatty acid transport in adipose tissue. JCI Insight. 2016 Jul 7;1(10):e86351.

[11]Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495-516.

[12]Fang Y, Kaszuba T, Imoukhuede PI. Systems Biology Will Direct Vascular-Targeted Therapy for Obesity. Front Physiol. 2020;11:831. Published 2020 Jul 15.

[13]Kim DH, Woods SC, Seeley RJ. Peptide designed to elicit apoptosis in adipose tissue endothelium reduces food intake and body weight. Diabetes. 2010 Apr;59(4):907-15.

[14]”Prohibitin-targeting peptide 1″. NCI Drug Dictionary. National Cancer Institutes. 2 February 2011.

[15]”Blood vessel mapping reveals four new ‘ZIP codes'”. medicalxpress. 24 October 2011. Retrieved 10 November 2011.

Author of this article:

Dr. Jean Zeng graduated from king’s college london Faculty of Life Sciences & Medicine. 

Scientific Journal paper Author:

1.Kirstin F. Barnhart

Department of Veterinary Science and Keeling Center for Comparative Medicine and Research, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.

2.Dong-Hoon Kim
Department of Pharmacology, Korea University College of Medicine, Seoul, Republic of Korea

3.Dr David Preiss
MRC Population Health Research Unit, Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, UK

4.Rae-Chi Huang
Telethon Kids Institute, University of Western Australia, Nedlands, Western Australia, Australia

5.Frédéric Thuaud
Therapeutic Innovation Laboratory (UMR 7200), CNRS/Université de Strasbourg, Faculté de Pharmacie, France

In no way does this doctor/scientist endorse or advocate the purchase, sale, or use of this product for any reason. peptide.ltd has no affiliation or relationship, implied or otherwise, with this physician. The purpose of citing this doctor is to acknowledge, acknowledge and commend the exhaustive research and development work done by the scientists working on this peptide.

Author of this article:

Dr. Jean Zeng graduated from king's college london Faculty of Life Sciences & Medicine.

Scientific Journal paper Author:

Stephen C. Bain
Diabetes Research Group, Swansea University Medical School, Swansea, SA2 8PP, UK
Department of Diabetes and Endocrinology, Singleton Hospital, Swansea Bay University Health Board, Swansea, SA2 8QA, UK

In no way does this doctor/scientist endorse or advocate the purchase, sale, or use of this product for any reason. Polypeptide.ltd has no affiliation or relationship, implied or otherwise, with this physician. The purpose of citing this doctor is to acknowledge, acknowledge and commend the exhaustive research and development work done by the scientists working on this peptide.